Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
ROCKVILLE, Md., Oct. 24, 2017 -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report the financial results for the third quarter of 2017 after 5:00 PM ET on Monday, November 6, 2017.
Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the third quarter 2017 business results on Tuesday, November 7, 2017 at 9:00 AM ET. Following the management presentation, the call will be open for questions.
A live webcast will be available at www.supernus.com.
Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.
| Conference dial-in: | (877) 288-1043 | |
| International dial-in: | (970) 315-0267 | |
| Conference ID: | 2899017 | |
| Conference Call Name: | Supernus Pharmaceuticals 3Q 2017 Earnings Conference Call |
Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company currently markets Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy. The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.
CONTACTS:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: [email protected]
